These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8691623)

  • 1. [Current advancement of assay of tumor markers and the perspective in future].
    Kawamura T
    Nihon Rinsho; 1996 Jun; 54(6):1642-8. PubMed ID: 8691623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cancer detection and prevention].
    Fujimoto H; Kawamura T; Koizumi F; Ishimori A
    Rinsho Byori; 1991 Apr; 39(4):352-60. PubMed ID: 2051613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical preventive medicine in cancer diagnosis--proposal for a new cancer diagnostic system in an aging society].
    Ishimori A
    Rinsho Byori; 1993 Jun; 41(6):617-24. PubMed ID: 8361026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [An evaluation of tumor markers and risk factors in mass screening for various cancers].
    Fujimoto H; Sasaki Y; Kawamura T; Ishimori A; Yanagiya T; Saita T
    Rinsho Byori; 1993 Jun; 41(6):642-8. PubMed ID: 8361030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A protein chip system for parallel analysis of multi-tumor markers and its application in cancer detection.
    Sun Z; Fu X; Zhang L; Yang X; Liu F; Hu G
    Anticancer Res; 2004; 24(2C):1159-65. PubMed ID: 15154641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early diagnosis of lung cancer by detection of tumor liberated protein.
    Tarro G; Perna A; Esposito C
    J Cell Physiol; 2005 Apr; 203(1):1-5. PubMed ID: 15389637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical evaluation on an enzyme immunoassay kit for basic fetoprotein (BFP). (2) Comparison and combination of BFP with other tumor markers].
    Ishii M; Hattori N; Kato T; Mochizuki M; Kamidono S; Sawabu N; Kawada Y; Kawai T; Abe O; Ohkura H
    Gan To Kagaku Ryoho; 1988 Jul; 15(7):2115-23. PubMed ID: 2456040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
    Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early detection of lung cancers - Comparison of computed tomography, cytology and fuzzy-based tumor markers panels.
    Schneider J
    Cancer Biomark; 2010; 6(3-4):149-62. PubMed ID: 20660961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of mucin-specific monoclonal antibodies and lectins in the detection of tumor-associated serum markers in gynecological cancer.
    Devine PL; McGuckin MA; Ramm LE; Harada H; Ward BG
    Cancer Biochem Biophys; 1993 Sep; 13(4):221-38. PubMed ID: 8521372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Sensitivity and specificity of tumor markers in cancer diagnosis].
    Motoo Y; Watanabe H; Sawabu N
    Nihon Rinsho; 1996 Jun; 54(6):1587-91. PubMed ID: 8691613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
    Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients.
    Schneider J; Peltri G; Bitterlich N; Philipp M; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
    Clin Exp Med; 2003 Feb; 2(4):185-91. PubMed ID: 12624710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?
    Ebert W; Muley T; Drings P
    Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
    Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
    Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved sensitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-PK.
    Schneider J; Bitterlich N; Schulze G
    Anticancer Res; 2005; 25(3A):1507-15. PubMed ID: 16033052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
    Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
    Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
    Jiang XT; Tao HQ; Zou SC
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of serum CYFRA 21-1 in lung cancer.
    Muraki M; Tohda Y; Iwanaga T; Uejima H; Nagasaka Y; Nakajima S
    Cancer; 1996 Apr; 77(7):1274-7. PubMed ID: 8608502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.